NTLA vs. BMY
NTLA (Intellia Therapeutics, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — NTLA in Biotechnology, BMY in Drug Manufacturers - General. Over the past 10 years, NTLA returned -5.06%/yr vs 2.16%/yr for BMY. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
NTLA vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NTLA achieves a 18.80% return, which is significantly lower than BMY's 25.17% return. Over the past 10 years, NTLA has underperformed BMY with an annualized return of -5.06%, while BMY has yielded a comparatively higher 2.16% annualized return.
NTLA
- 1D
- -3.70%
- 1M
- -39.18%
- 6M
- -18.78%
- YTD
- 18.80%
- 1Y
- -7.05%
- 3Y*
- -36.11%
- 5Y*
- -40.39%
- 10Y*
- -5.06%
- ALL TIME*
- -6.82%
BMY
- 1D
- 0.69%
- 1M
- 12.35%
- 6M
- 21.21%
- YTD
- 25.17%
- 1Y
- 54.75%
- 3Y*
- 6.92%
- 5Y*
- 3.38%
- 10Y*
- 2.16%
- ALL TIME*
- 9.43%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $711.50M | $665.03M | $681.59M | |
| $37.16M | $55.27M | $78.35M |
NTLA vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 18.80% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 270.82% | 7.47% | -28.98% | 46.61% |
BMY Bristol-Myers Squibb Company | 25.17% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between NTLA and BMY is 0.11, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.11 |
Correlation (3Y) Balances recent behavior with more history. | 0.21 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.18 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.21 |
Correlation (All Time) Calculated using the full available price history since May 6, 2016 | 0.21 |
The correlation between NTLA and BMY shifts across timeframes, from 0.11 (1 year) to 0.21 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
NTLA:
$1.20B
BMY:
$133.37B
NTLA:
-$3.51
BMY:
$4.54
NTLA:
18.16
BMY:
2.71
NTLA:
2.04
BMY:
5.99
NTLA:
$66.09M
BMY:
$49.19B
NTLA:
-$33.92M
BMY:
$34.51B
NTLA:
-$299.32M
BMY:
$16.67B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NTLA vs. BMY — Risk / Return Rank
NTLA
BMY
NTLA vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NTLA | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.23 | ||
| Sortino ratioReturn per unit of downside risk | -2.46 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.36 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | -0.12 | 4.66 | -4.77 |
| Martin ratioReturn relative to average drawdown | -0.17 | 11.09 | -11.26 |
Loading charts...
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -96.45%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY.
Loading charts...
Drawdown Indicators
| NTLA | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.45% | -72.03% | -24.42% |
Max Drawdown (1Y)Largest decline over 1 year | -71.27% | -12.53% | -58.74% |
Max Drawdown (3Y)Largest decline over 3 years | -84.31% | -34.11% | -50.20% |
Max Drawdown (5Y)Largest decline over 5 years | -96.45% | -47.67% | -48.78% |
Max Drawdown (10Y)Largest decline over 10 years | -96.45% | -47.67% | -48.78% |
Current DrawdownCurrent decline from peak | -93.96% | -4.95% | -89.01% |
Average DrawdownAverage peak-to-trough decline | -57.56% | -22.36% | -35.20% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.81% | 5.25% | +43.56% |
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 18.85% compared to Bristol-Myers Squibb Company (BMY) at 9.10%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NTLA | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.85% | 9.10% | +9.75% |
Volatility (6M)Calculated over the trailing 6-month period | 56.80% | 19.64% | +37.16% |
Volatility (1Y)Calculated over the trailing 1-year period | 98.08% | 27.86% | +70.22% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.01% | 24.49% | +53.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.82% | 25.46% | +53.36% |
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 3.84%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 3.84% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NTLA and BMY have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (18.85%) compared to BMY (9.10%). In terms of maximum drawdown, NTLA dropped -96.45% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (2.14 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NTLA and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer